-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2399 CD34 Is a Ligand for Vascular Selectins on Human Hematopoietic Stem/Progenitor Cells

Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion and Stromal Stem Cells
Program: Oral and Poster Abstracts
Session: 506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion and Stromal Stem Cells: Poster II
Sunday, December 6, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Dina Bashir AbuSamra, MScs

Division of Biological and Environmental Sciences and Engineering (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia

The cell surface glycoprotein CD34 is widely recognized as a marker of hematopoietic stem/progenitor cells (HSPCs), but its physiological role on HSPCs remains elusive. Although CD34 is well recognized for mediating homing of L-selectin+ naïve T cells to high endothelial venules of secondary lymphoid organs, the natural ligand for HSPC specific-CD34 is unknown. Studies in both humans and mice indicate that vascular selectins (E-selectin and P-selectin) are constitutively expressed on marrow endothelial cells and intravital studies revealed that HSPC migration to marrow occurs at specialized microvascular beds expressing E-selectin. Given that the identity of these glycoprotein E-selectin ligands (E-selL) on human HSPCs is limited, we used mass spectrometry (MS)-based proteomics to fully characterize all these potential ligands expressed on primary human CD34+ HSPCs and on the CD34+ KG1a cell line (human acute myelogenous leukemia that serves as a model for human HSPCs). We obtained a very rich resource for further investigation and chose to highlight CD34 as an E-selL candidate. The physiological binding of CD34 to E-selectin was addressed at both the molecular level and cellular level using novel binding assays. At the molecular level we developed a novel-binding assay to capture endogenous candidate glycoprotein ligands from whole cell lysates prepared from human HSPCs onto a surface plasmon resonance (SPR) chip and characterized its binding kinetics to recombinant E-sel. At the cellular level we used the blot rolling assay to monitor the ability of cells stably transfected with E-selectin (CHO-E) to roll on CD34 immunoprecipitated from HSPCs to demonstrate that CD34 binds to E-selectin with affinity comparable to well-described E-selectin ligands. Further biochemical analysis demonstrated that E-selectin binding was restricted to a specific glycoform that expresses sialyl Lewis X (sLex). This interaction was dependent on calcium, sialylation and O-glycans as removal of these abolished binding to E-selectin. CD34 binding to the other vascular selectin, P-selectin was dependent on O-glycan and tyrosine sulfation making CD34 the first selectin ligand since P-selectin glycoprotein ligand-1 (PSGL-1) reported to bind all three selectins. Among the stem cell specific processes such as self-renewal and differentiation that CD34 has been implicated to play a significant role in, these data are the first to define a role for human CD34 in mediating the direct migration of HSPCs to the bone marrow and suggests that a natural ligand for CD34 on human HSPCs are vascular selectins.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH